The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis
Open accessAbstract
BACKGROUND: Neurosurgical resection is the standard treatment for subependymal giant-cell astrocytomas in patients with the tuberous sclerosis complex. An alternative may be the use of everolimus, which inhibits the mammalian target of rapamycin, a protein regulated by gene products involved in the tuberous sclerosis complex. METHODS: Patients 3 years of age or older with serial growth of subependymal giant-cell astrocytomas were eligible for this open-label study. The primary efficacy end point was the change in volume of subependymal giant-cell astrocytomas between baseline and 6 months. We gave everolimus orally, at a dose of 3.0 mg per square meter of body-surface area, to achieve a trough concentration of 5 to 15 ng per milliliter. RESULTS: We enrolled 28 patients. Everolimus therapy was associated with a clinically meaningful reduction in volume of the primary subependymal giant-cell astrocytoma, as assessed on independent central review (P<0.001 for baseline vs. 6 months), with a reduction of at least 30% in 21 patients (75%) and at least 50% in 9 patients (32%). Marked reductions were seen within 3 months and were sustained. There were no new lesions, worsening hydrocephalus, evidence of increased intracranial pressure, or necessity for surgical resection or other therapy for subependymal giant-cell astrocytoma. Of the 16 patients for whom 24-hour video electroencephalography data were available, seizure frequency for the 6-month study period (vs. the previous 6-month period) decreased in 9, did not change in 6, and increased in 1 (median change, -1 seizure; P=0.02). The mean (±SD) score on the validated Quality-of-Life in Childhood Epilepsy questionnaire (on which scores can range from 0 to 100, with higher scores indicating a better quality of life) was improved at 3 months (63.4±12.4) and 6 months (62.1±14.2) over the baseline score (57.8±14.0). Single cases of grade 3 treatment-related sinusitis, pneumonia, viral bronchitis, tooth infection, stomatitis, and leukopenia were reported. CONCLUSIONS: Everolimus therapy was associated with marked reduction in the volume of subependymal giant-cell astrocytomas and seizure frequency and may be a potential alternative to neurosurgical resection in some cases, though long-term studies are needed. (Funded by Novartis; ClinicalTrials.gov number, NCT00411619.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Tuberous Sclerosis Complex
Crino, P. B., Nathanson, K. L., & Henske, E. P. (2006) · New England Journal of Medicine · doi:10.1056/nejmra055323 · Cited by 1,793
Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis
Bissler, J. J., McCormack, F. X., Young, L. R., Elwing, J. M., Chuck, G., Leonard, J. M., Schmithorst, V. J., Laor, T., Brody, A. S., Bean, J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa063564 · Cited by 1,253
Self-citationThe TSC1–TSC2 complex: a molecular switchboard controlling cell growth
Huang, J., & Manning, B. D. (2008) · Biochemical Journal · doi:10.1042/bj20080281 · Cited by 1,237
mTOR signaling: At the crossroads of plasticity, memory and disease
Hoeffer, C. A., & Klann, E. (2010) · Trends in Neurosciences · doi:10.1016/j.tins.2009.11.003 · Cited by 1,128
Tuberous Sclerosis Complex Consensus Conference: Revised Clinical Diagnostic Criteria
Roach, E. S., Gomez, M. R., & Northrup, H. (1998) · Journal of Child Neurology · doi:10.1177/088307389801301206 · Cited by 1,081
Rapamycin causes regression of astrocytomas in tuberous sclerosis complex
Franz, D. N., Leonard, J., Tudor, C., Chuck, G., Care, M., Sethuraman, G., Dinopoulos, A., Thomas, G., & Crone, K. R. (2006) · Annals of Neurology · doi:10.1002/ana.20784 · Cited by 614
Self-citationEaston, J. B., & Houghton, P. J. (2006) · Oncogene · doi:10.1038/sj.onc.1209886 · Cited by 459
Subependymal giant cell tumors in tuberous sclerosis complex
Goh, S., Butler, W., & Thiele, E. A. (2004) · Neurology · doi:10.1212/01.wnl.0000142039.14522.1a · Cited by 262
Chan, J. A., Zhang, H., Roberts, P. S., Jozwiak, S., Wieslawa, G., Lewin-Kowalik, J., Kotulska, K., & Kwiatkowski, D. J. (2004) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/63.12.1236 · Cited by 258
The Growing Role of mTOR in Neuronal Development and Plasticity
Jaworski, J., & Sheng, M. (2006) · Molecular Neurobiology · doi:10.1385/mn:34:3:205 · Cited by 239
Adriaensen, M. E. A. P. M., Schaefer‐Prokop, C. M., Stijnen, T., Duyndam, D. A. C., Zonnenberg, B. A., & Prokop, M. (2009) · European Journal of Neurology · doi:10.1111/j.1468-1331.2009.02567.x · Cited by 187
Glutamatergic Regulation of the p70S6 Kinase in Primary Mouse Neurons
Lenz, G., & Avruch, J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.c500363200 · Cited by 143
Validation of the Quality of Life in Childhood Epilepsy Questionnaire in American epilepsy patients
Sabaz, M., Lawson, J. A., Cairns, D. R., Duchowny, M. S., Resnick, T. J., Dean, P. M., & Bye, A. M. E. (2003) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2003.08.012 · Cited by 136
Hofbauer, G. F. L., Marcollo-Pini, A., Corsenca, A., Kistler, A. D., French, L. E., Wthrich, R. P., & Serra, A. L. (2008) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2008.08677.x · Cited by 135
SUBEPENDYMAL GIANT-CELL ASTROCYTOMASIN PEDIATRIC TUBEROUS SCLEROSIS DISEASE
de Ribaupierre, S., Dorfmüller, G., Bulteau, C., et al. (2007) · Neurosurgery · doi:10.1227/01.neu.0000249216.19591.5d · Cited by 132
The pathogenesis and imaging of the tuberous sclerosis complex
Baskin, H. J. (2008) · Pediatric Radiology · doi:10.1007/s00247-008-0832-y · Cited by 123
Antitumoral Activity of Rapamycin in Renal Angiomyolipoma Associated With Tuberous Sclerosis Complex
Wienecke, R., Fackler, I., Linsenmaier, U., Mayer, K., Licht, T., & Kretzler, M. (2006) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.05.018 · Cited by 118
Rapamycin Reduces Seizure Frequency in Tuberous Sclerosis Complex
Muncy, J. L., Butler, I. J., & Koenig, M. K. (2009) · Journal of Child Neurology · doi:10.1177/0883073808324535 · Cited by 112
Bruyn, G. A. W., Tate, G., Caeiro, F., Maldonado-Cocco, J. A., Westhovens, R., Tannenbaum, H., Bell, M. M., Førre, Ø., Bjørneboe, O., Tak, P. P., et al. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.078808 · Cited by 109
Regression of Subependymal Giant Cell Astrocytoma With Rapamycin in Tuberous Sclerosis Complex
Koenig, M. K., Butler, I. J., & Northrup, H. (2008) · Journal of Child Neurology · doi:10.1177/0883073808321764 · Cited by 81
Callan, K. (2008) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2008.0001 · Cited by 76
Current Management of Tuberous Sclerosis Complex
Krueger, D. A., & Franz, D. N. (2008) · Pediatric Drugs · doi:10.2165/00148581-200810050-00004 · Cited by 67
Self-citationEverolimus: an update on the mechanism of action, pharmacokinetics and recent clinical trials
Sánchez-Fructuoso, A. I. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.6.807 · Cited by 62
NCCN Task Force Report: mTOR Inhibition in Solid Tumors
Figlin, R. A., Brown, E., Armstrong, A. J., Akerley, W., Benson, A. B., Burstein, H. J., Ettinger, D. S., Febbo, P. G., Fury, M. G., Hudes, G. R., et al. (2008) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2008.2005 · Cited by 49
Sirolimus Treatment for Pulmonary Lymphangioleiomyomatosis
Taillé, C., Debray, M., & Crestani, B. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-9-200705010-00022 · Cited by 42
Morton, J. M., McLean, C., Booth, S. S., Snell, G. I., & Whitford, H. M. (2008) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2008.01.005 · Cited by 39
mTOR in Tuberous Sclerosis and other Neurological Disorders
Franz, D. (2007) · Epilepsia · doi:10.1111/j.1528-1167.2007.01178_2.x · Cited by 8
Self-citation
Cited by
Jiao, Y., Shi, C., Edil, B. H., de Wilde, R. F., Klimstra, D. S., Maitra, A., Schulick, R. D., Tang, L. H., Wolfgang, C. L., Choti, M. A., et al. (2011) · Science · doi:10.1126/science.1200609 · Cited by 1,717
Northrup, H., Krueger, D. A., Northrup, H., Krueger, D. A., Roberds, S., Smith, K., Sampson, J., Korf, B., Kwiatkowski, D. J., Mowat, D., et al. (2013) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2013.08.001 · Cited by 1,502
Self-citationEpidemiologic and Molecular Prognostic Review of Glioblastoma
Thakkar, J. P., Dolecek, T. A., Horbinski, C., Ostrom, Q. T., Lightner, D. D., Barnholtz-Sloan, J. S., & Villano, J. L. (2014) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-14-0275 · Cited by 1,390
Jacob, F., Salinas, R. D., Zhang, D. Y., Nguyen, P. T. T., Schnoll, J. G., Wong, S. Z. H., Thokala, R., Sheikh, S., Saxena, D., Prokop, S., et al. (2020) · Cell · doi:10.1016/j.cell.2019.11.036 · Cited by 1,149
Weller, M., Wick, W., Aldape, K., Brada, M., Berger, M., Pfister, S. M., Nishikawa, R., Rosenthal, M., Wen, P. Y., Stupp, R., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.17 · Cited by 1,124
Metadata
- Authors
- Krueger, D. A., Care, M. M., Holland, K., Agricola, K., Tudor, C., Mangeshkar, P., Wilson, K. A., Byars, A., Sahmoud, T., & Franz, D. N.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-11-04
- Volume
- 363
- Issue
- 19
- Pages
- 1801-1811
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2035495486
- Cited by
- 1,006
- References
- 27
- FWCI
- 56.88
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.